ATRX - Antibodies - The Human Protein Atlas

We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.

ATRX

TISSUE

CELL

CANCER

ANTIBODY INFORMATION

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Provider

Atlas Antibodies
Sigma-Aldrich

Santa Cruz Biotechnology

Atlas Antibodies
Sigma-Aldrich

Product name

HPA001906

HPA064684

sc-15408

AMAb90784

Host species

Rabbit

Mouse

Clonality

pAb

mAb

Purity

Affinity purified using the PrEST-antigen as affinity ligand

Protein A/G

Other gene match

Released in version

References

VALIDATION SUMMARY

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Immunocytochemistry

Immunohistochemistry

Western blot

Protein array

IMMUNOCYTOCHEMISTRY

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Standard validation

Supported

Figure description

Immunofluorescent staining of human cell line SH-SY5Y shows localization to nuclear bodies.

Antibody dilution

1:200

Literature conformity

The subcellular location is supported by literature.

IMMUNOHISTOCHEMISTRY

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Standard validation

Supported

Figure description

Immunohistochemical staining of human pancreas shows moderate nuclear positivity in exocrine glandular cells and in islets of Langerhans.

Immunohistochemical staining of human pancreas shows strong nuclear positivity in exocrine glandular cells and in islets of Langerhans.

Expression

RNA: detected in 37 tissues
Protein: detected in 70 cell types

RNA: detected in 37 tissues
Protein: detected in 74 cell types

RNA: detected in 37 tissues
Protein: detected in 71 cell types

Retrieval

HIER pH6

Antibody dilution

1:1500

1:300

1:500

Literature conformity

Partly consistent with extensive gene/protein characterization data.

Consistent with extensive gene/protein characterization data.

Partly consistent with extensive gene/protein characterization data.

RNA consistency

Mainly consistent with RNA expression data.

WESTERN BLOT

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Standard validation

Uncertain

Analysis performed using a standard panel of samples.
Target too small/large to be analyzed with the present setup.

Uncertain

Analysis performed using a standard panel of samples.
Only bands not corresponding to the predicted size.

Supported

Analysis performed using a standard panel of samples.
Band of predicted size in kDa (+/-20%) with additional bands present.

Supported

Analysis performed using a standard panel of samples.
Single band corresponding to the predicted size in kDa (+/-20%).

Figure description

Lane 1: Marker [kDa] 220, 112, 84, 47, 32, 26, 16.8
Lane 2: RT4
Lane 3: U-251 MG
Lane 4: Human Plasma
Lane 5: Liver
Lane 6: Tonsil

Lane 1: Marker [kDa] 250, 130, 100, 70, 55, 35, 25, 15, 10
Lane 2: RT4
Lane 3: U-251 MG
Lane 4: Human Plasma
Lane 5: Liver
Lane 6: Tonsil

Target mass (kDa)

282.6, 278.2

282.6, 278.2, 151.7, 107, 59.4

282.6, 278.2, 151.7, 107, 59.4, 33.1, 22.9, 22.2, 12, 5

Antibody dilution

1:250

1:720

1:500

1:1000

PROTEIN ARRAY

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Standard validation

Approved

Pass with quality comment low specificity (binding to 1-2 PrESTs >15% and <40%).

Supported

Pass with single peak corresponding to interaction only with its own antigen.

Figure description

Antibody specificity analysis with protein arrays. Predicted and matching interactions are shown in green.

Antibody dilution

1:3000

1:8600

ANTIGEN INFORMATION

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Antigen

Recombinant protein fragment

Recombinant protein

Length (aa)

141

Antigen sequence

AAWAEYEAEKKGLTMRFNIPTGTNLPPVSFNSQTPYIPFNLGALSAMSNQ
QLEDLINQGREKVVEATNSVTAVRIQPLEDIISAVWKENMNLSEAQVQAL
ALSRQASQELDVKRREAIYNDVLTKQQMLISCVQRILMNRR

EFRAMDAVNKEKNTKEHKVIDAKFETKARKGEKPCALEKKDISKSEAKLS
RKQVDSEHMHQNVPTEEQRTNKSTGGEHKKSDRKEEPQYEPANTSE

Matching transcripts

ATRX-001 - ENSP00000362441 [100%]
ATRX-002 - ENSP00000378967 [100%]

ATRX-001 - ENSP00000362441 [100%]
ATRX-002 - ENSP00000378967 [100%]
ATRX-004 - ENSP00000485253 [100%]
ATRX-009 - ENSP00000485127 [100%]
ATRX-010 - ENSP00000485103 [100%]

Other gene match

ANTIGEN VIEW

ATRX-001	ATRX-002	ATRX-004	ATRX-009	ATRX-010

RELEVANT PUBLICATIONS

Antibody HPA001906

Antibody HPA064684

Antibody CAB009372

Antibody CAB068176

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber J et al
Nature 2012;482(7384):226-31

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway
Lovejoy CA et al
PLoS Genet 2012;8(7):e1002772

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
de Wilde RF et al
Mod Pathol 2012;25(7):1033-9

Altered telomeres in tumors with ATRX and DAXX mutations
Heaphy CM et al
Science 2011;333(6041):425

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas
Abedalthagafi M et al
Mod Pathol 2013;26(11):1425-32

Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Haberler C et al
Clin Neuropathol ;33(2):108-11

Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas
Nguyen DN et al
Brain Pathol 2013;23(3):237-43

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao Y et al
Oncotarget 2012;3(7):709-22
Application: IHC

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
Cryan JB et al
Oncotarget 2014;5(18):8083-92
Application: IHC

10.

Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
Barszczyk M et al
Acta Neuropathol 2014;128(6):863-77
Application: IHC

11.

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Fishbein L et al
Nat Commun 2015;6:6140
Application: IHC

12.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH
Cairncross JG et al
J Clin Oncol 2014;32(8):783-90
Application: IHC

13.

TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Yoshida M et al
Br J Cancer 2015;113(8):1244-8
Application: IHC

14.

Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort
Hayashi S et al
Oncotarget 2015;6(18):15871-81
Application: IHC

15.

ATRX represses alternative lengthening of telomeres
Napier CE et al
Oncotarget 2015;6(18):16543-58
Application: WB

16.

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
Mäkinen N et al
PLoS Genet 2016;12(2):e1005850
Application: IHC

17.

ATRX binds to atypical chromatin domains at the 3' exons of zinc finger genes to preserve H3K9me3 enrichment
Valle-García D et al
Epigenetics 2016;11(6):398-414
Application: IP

Contact

contact@proteinatlas.org

The Project

The Human Protein Atlas

The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.